White & Case Advises Angelini Pharma on Up to US$960 Million Acquisition of Arvelle Therapeutics
1 min read
Global law firm White & Case LLP has advised international pharma and consumer healthcare group Angelini Pharma on the acquisition of Arvelle Therapeutics, a biopharmaceutical group headquartered in Switzerland focused on developing innovative treatments for patients with central nervous system disorders, for up to US$960 million.
Established in 1919, the Angelini Group, of which Angelini Pharma is a part, is a privately-owned Italian pharma and consumer healthcare group with an international presence and brands including Trittico, Tantum, Aulin, Latuda, Boxagrippal and Thermacare. It is one of the top pharmaceutical companies in Italy, noted for self-medication via products with brands including Tachipirina, Moment, Amuchina and Tantum Verde.
Following the acquisition of Arvelle Therapeutics, Angelini Pharma will have the exclusive license to commercialize cenobamate in the European Union and other countries in the European Economic Area, including Switzerland and the United Kingdom, becoming one of the main players in the market for companies focused on the treatment of disorders to the central nervous system and mental health, and in particular for the treatment of epilepsy. The launch of cenobamate on the market is planned after it receives approval from the European Medicines Agency, which is expected in 2021.
The White & Case team that advised on the transaction comprised partners Ferigo Foscari, Leonardo Graffi, Tommaso Tosi (all Milan), Peita Menon (London), Axel Schulz (Brussels), Justus Herrlinger (Hamburg), Andres Liivak (New York), Farhad Jalinous, Keith Schomig (both Washington, DC) and Charles Larsen (Boston), local partner Alexandra Rogers (Brussels) and associates Sara Scapin, Niccolò Miglio, Nicole Paccara, (all Milan), Elizabeth Emerson (London), Iakovos Sarmas (Brussels) and Louisa Maier-Witt (Hamburg) and lawyer Olga Primiani (Milan).
For more information please speak to your local media contact.